My watch list  


Systematic (IUPAC) name
CAS number 31883-05-3
ATC code  ?
PubChem 34633
DrugBank APRD01124
Chemical data
Formula C22H25N3O4S 
Mol. mass 427.518 g/mol
Pharmacokinetic data
Bioavailability 38%
Protein binding 95%
Metabolism  ?
Half life 3-4 hours (healthy volunteers), 6-13 hours (cardiac disease)
Excretion  ?
Therapeutic considerations
Pregnancy cat.

B (U.S.)

Legal status
Routes  ?

Moricizine is a phenothiazine derivative with Vaughan Williams class IC antiarrhythmic properties. It undergoes extensive first-pass metabolism, has a bioavailability of 34-38 percent, and is 95 percent bound to plasma proteins. Moricizine is extensively metabolized and may have pharmacologically active metabolites. A recent clinical study has shown that moricizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations[citation needed]. Compared with disopyramide and quinidine, moricizine was equally or more effective in suppressing ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia[citation needed]. Further studies are needed comparing moricizine with other class 1 agents in the treatment of life-threatening arrhythmias; available data suggest that moricizine is comparable with these agents in the treatment of ventricular tachycardias and fibrillation. Moricizine appears to have a low incidence of serious adverse effects compared with other antiarrhythmics. This combination of apparently similar efficacy with a decreased incidence of adverse effects makes moricizine a worthwhile addition to currently available antiarrhythmic agents

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Moricizine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE